La Jolla Pharmaceutical Co

LJPCCIK 0000920465 · Every Form 4 filed by insiders at this issuer. See financials →

Annual report (10-K)

Latest 10-K/A filed May 2, 2022. Sentiment + YoY language diff vs prior year. Read sections →

Signal:NeutralFull-doc fallback

Full filing:tone 0.0016

Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.

YoY shift: Unscored

Year-over-year tone shift - average net-tone change across Risk Factors and MD&A vs the prior 10-K.

Why YoY instead of absolute: the LM lexicon has ~6.6× more negative words than positive (legal/risk-disclosure language is heavy on hedging), so every 10-K reads bearish on raw tone. Year-over-year change strips that bias and surfaces the actual shift in management's framing.

Per-snippet highlights

Sentence-level sentiment highlighting with category and subcategory filters is coming once the snippet-scoring pipeline lands. For now, dig into the actual section text on the Sections tab.

Top insiders

Most active reporters at La Jolla Pharmaceutical Co

Name	Roles	Filings
Hearne Michael S	Officer	13
Edwards Larry G.	Officer	9
Johnson Craig A	Director	1
Johnson Laura L.	Director	1
Ramsay David A	Director	1

Showing 1-5 of 7

Per pagePage 1 of 2Next

All filings

27 Form 4 / 4-A filings, newest first

Filed	Insider	Top transaction	Shares	Price	Value
Jun 17, 2022	Hearne Michael S Chief Financial Officer	AGrant	236	$2.72	$642
Jun 2, 2022	Hearne Michael S Chief Financial Officer	AGrant	189	$3.4085	$644
May 17, 2022	Hearne Michael S Chief Financial Officer	AGrant	188	$3.4085	$641
May 3, 2022	Hearne Michael S Chief Financial Officer	AGrant	185	$3.468	$642
Apr 18, 2022	Hearne Michael S Chief Financial Officer	AGrant	173	$3.7145	$643

Showing 1-5 of 27

Per pagePage 1 of 6Next

Real-time Form 4 intelligence. Smarter insider tracking.

Filed		Top transaction	Shares	Price	Value